Solid Tumor, Adult trials recruiting in California
All Solid Tumor, Adult trials nationally
19
Recruiting in California
14
Cities with sites
Cities in California
Los Angeles 10San Francisco 8La Jolla 5San Diego 5Duarte 3Stanford 3Orange 2Santa Monica 2Beverly Hills 1Newport Beach 1Palo Alto 1Redlands 1
Recruiting trials in California
- 64Cu-GRIP B in Patients With Advanced Malignancies
- A Beta-only IL-2 ImmunoTherapY Study
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies